The talk shall focus on the design of a novel nanoscale platform that enables the spatiotemporal targeting of tumor stroma and parenchyma with an antiangiogenic agemt followed by a cytotoxic. This enables the intratumoral exposure of the hypoxic tumor to a chemotherapeutic agent resulting in disruption of the HIF1a-autocrine loop and increased antitumor efficacy.